Network pharmacology and experimental evidence reveal the protective mechanism of Yi-Qi Cong-Ming decoction on age-related hearing loss

Yi-Fang Yang, Xi-Rui Yan, Rui-Xin Wu, Ning Li, Min Chu, Yang Dong, Shu-Ping Fu, Jian-Rong Shi and Qing Liu

ABSTRACT

Context: Yi-Qi Cong-Ming (YQCM) decoction has been widely used to prevent age-related hearing loss (ARHL), the most prevalent neurodegenerative disease in the elderly. Objective: To explore the mechanism of YQCM decoction in the treatment of ARHL. Materials and methods: The chemical constituents of YQCM were screened from the Traditional Chinese Medicine Systems Pharmacology Database. Potential targets of YQCM against ARHL were predicted by DrugBank, GeneCards, and OMIM database. Protein-protein network and enrichment analysis were used for exploring possible molecular mechanisms. Molecular docking and an in vitro model of ARHL by exposing auditory cells with 100 μM H2O2 for 3 h were applied. Cell viability and mitochondrial membrane potential (ΔΨM) were detected by CCK-8 and high-content analysis. γH2AX and cleaved caspase-3 were detected by Western blot. Results: The main compounds have good affinities with hub targets, especially AKT1, PTGS2, and CASP3. GO and KEGG analysis showed that the main biological process and key targets were related to negative regulation of the apoptotic process. H2O2 treatment could reduce the cell viability by 68% and impaired ΔΨM, while 90 μg/mL YQCM pre-treatment could restore the cell viability by 97.45% and increase ΔΨM (2-fold higher). YQCM pre-treatment also reduced γH2AX and cleaved caspase-3 protein levels. Conclusions: Our study suggested that YQCM prevents ARHL by modulating the apoptosis process in auditory hair cells. Moreover, this study proved that bioinformatics analysis combined with molecular docking and cell model is a promising method to explore other possible pharmacological interventions of ARHL.

Introduction

Age-related hearing loss (ARHL), also called presbycusis, is one of the universal features of mammalian ageing which is characterised by gradual, progressive, bilateral loss of hearing starting from a high-frequency region of the hearing spectrum (Yamasoba et al. 2013). It is the third leading cause of chronic disability in older adults (Livingston et al. 2017; Loughrey et al. 2018) and influences approximately one-third of people aged over 65 (Patel and McKinnon 2018). Hearing loss not only affects the hearing quality, but is also associated with loneliness, social isolation (Maharani et al. 2019), and an increased risk of cognitive decline in older adults (Lin and Albert 2014; Jafari et al. 2019; Livingston et al. 2020). The most common method of hearing rehabilitation in presbycusis is the prescription of hearing aids and cochlear implants. Hearing aids are designed to replace the amplification and compression that are no longer provided by the outer hair cells, the sensory-motor cells of the mammalian cochlea. This approach can improve the perception of weak sounds in quiet environments. However, for high-intensity sounds in background noise, the aids often fail to restore the perception of speech (Armstrong et al. 2022). Therefore, only a small fraction (10–20%) of older people with significant impairment use a hearing aid (McCormack and Fortnum 2013). Although cochlear implants can bypass damaged hair cells by providing direct electrical stimulation of spiral ganglion neurons (SGNs), the beneficial effects of cochlear implants are also strongly limited in elderly populations due to SGNs degeneration (Shibata et al. 2011). Apart from these challenges, the high cost of cochlear implants also imposes a significant financial burden on users. Thus, it is urgent to make efforts in pharmacological prevention and treatment to delay the occurrence and development of ARHL.

During the process of ARHL, three dominant morphological changes occur in the ageing cochlea: (1) the loss of sensory hair cells, which are responsible for the conversion of sound stimulation to neural impulses; (2) the loss of SGNs, which serve as the primary carrier of auditory information; (3) the atrophy of the stria vascularis (SV) of the cochlear lateral wall of scala media, which maintains endolymph potential (Keithley 2020). The exact mechanisms behind morphological changes are still being explored, but over time more evidence has come to light supporting the theory that oxidative stress (Tavanai and Mohammadkhani 2017; Pak et al. 2020) and inflammation...
(Verschuur et al. 2012; Uraguchi et al. 2021) incur the deleterious effects to this damage. Yi-qi Cong-ming (YQCM), a famous decoction composed of 8 herbs including Ginseng radix et rhizome (Panax ginseng C.A.Mey. [Araliaceae]), Astragali radix (Astragalus mongholicus Bunge, [Fabaceae]), Glycyrrhizae radix et rhizome (Glycyrrhiza uralensis) Fisch. ex DC. [Fabaceae]), Cimicifugae rhizome (Actaea cimicifuga L. [Ranunculaceae]), Puerariae lobatae radix (Pueraria montana var. lobata (Willd.) Maesen & S.M.Almeida ex Sanjappa & Predeep [Fabaceae]), Viticis fructus (Vitex trifolia L. [Lamiaceae]), Paeoniae radix alba (Paeonia lactiflora Pall. [Paeoniaceae]), and Phellodendri chinensis chinensis (Phellodendron chinense C.K.Schneid. [Rutaceae]). This Traditional Chinese formula has been widely used to prevent early signs of ageing in Chinese society for centuries, particularly helpful for the treatment of neurodegenerative diseases in older, such as Alzheimer's disease (Kang et al. 2021), dementia (Qin et al. 2019), vertigo, and presbycusis (Wei et al. 2017). The clinical trial has shown that the total effective rate of clinical treatment of deafness with YQCM decoction is 89.19%, and a follow-up survey of patients with significant effects has been carried out and no recurrence was found (Wei et al. 2017). Similar final efficiency rates were reported as well in the clinical trial conducted by Li (Li 2013). Ginseng radix et rhizoma and Astragali radix, the main components of YQCM, have been demonstrated to improve hearing thresholds in patients with sensorineural hearing loss and alleviate the symptoms of tinnitus (Xiong et al. 2011; Tian et al. 2014). At present, most of the studies on YQCM decoction in the prevention and treatment of ARHL are from clinical trials, but the molecular mechanisms underlying the therapeutic effects of this prescription remain unclear. Studies based on molecular targets and related signal pathways of this prescription action on ARHL are limited. Thus, further research with the appropriate approaches is needed to comprehensively reveal the involved potential mechanisms, which will provide a scientific basis for clinical trial research and product development of YQCM decoction. In this paper, we construct a multidimensional network of component-target-pathway-disease by using network pharmacology. Gene Ontology (GO), and pathway enrichment analyses were performed to further reveal the biological mechanism of action of YQCM against ARHL. In addition, molecular docking and in vitro experiments were used to confirm the key mechanism for its action. The findings may provide new reference information for the further development and application of YQCM. The idea of this study is shown in the flow chart in Figure 1.

Materials and methods

Identify the chemical constituents of YQCM decoction

The chemical composition information of eight traditional Chinese medicines in YQCM decoction was obtained by using the Traditional Chinese medicine systems pharmacology database and analysis platform, TCMSP Version 2.3. Two parameters, oral bioavailability (OB) and drug-likeness (DL) were used to screen the above compounds, and the chemical components with both OB ≥ 30% and DL ≥ 0.18 were selected as potentially effective chemical components.

Prediction of targets and construction of the visual network of ingredient-action target

Based on the identified components, the corresponding targets were predicted by DrugBank online database (access: Feb 17, 2020, https://go.drugbank.com). We used “Age-related hearing loss” and “Presbycusis” as the keywords in the GeneCards database (access: Feb 25, 2020, https://www.genecards.org) and Online Mendelian Inheritance in Man database (access: Feb 25, 2020; OMIM database, https://www.omim.org) to search potential targets of ARHL. The visualisation network of the ingredient-action target was established by Cytoscape 3.6.0. Then the Network Analyser plug-in is used to analyse the network diagram to find its main active components and important targets.

Construction of protein-protein interaction (PPI) network and enrichment analysis

The common targets of disease and drug are obtained by using the Venny online tools, that is, the potential target of YQCM decoction in the prevention and treatment of presbycusis. The drug-disease common target was introduced into the STRING: functional protein association networks. The PPIs with medium confidence were included in this study. Subsequently, a PPI network for the potential target was constructed using Cytoscape. The “Network Analyser” plug-in of Cytoscape software is used to analyse the topological attributes of the PPI network. The topological parameters, including Degree, Betweenness, and Closeness, were applied for screening core targets. To explore the mechanism underlying YQCM’s effect on ARHL, the Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway and GO including cellular components (CC), biological processes (BP), and molecular functions (MF) were analysed by the database for annotation, visualisation, and integrated discovery (DAVID) tools (version 6.8, https://david.ncifcrf.gov). The statistical significance threshold of enrichment analysis was established at p < 0.05.

Molecular docking

The crystal structures of the target were retrieved from the RCSB (https://www.rcsb.org/) database. Three-dimensional structures of the target were retrieved from the PubChem database and minimised using MMFF94 forcefield. The water molecules and original ligands were removed by PyMol 2.5 software and transferred to pdbqt format via AD4F suite 1.0. Subsequently, AutoDock Vina 1.1.2 was employed for molecular docking to evaluate the binding affinity between core potential targets and core compounds. The binding activity is evaluated by the binding energy (kJ/mol). The smaller the binding energy, the more stable the docking module. The minimum binding energy <−5.0 kcal/mol indicates a good binding affinity between receptor and ligand (Yang et al. 2021; Zhang et al. 2021).

Molecular dynamics simulation

After docking, the molecular dynamics (MD) simulation strategy was carried out to simulate the binding stability of the receptor and ligand by the AMBER 18 software package (Park et al.
The atomic partial charges of the ligands were obtained by the restrained electrostatic potential fitting method (Wang et al. 2000) based on the electrostatic potentials computed at the Hartree-Fock SCF/6-31G* level of theory. Subsequently, the AMBER force field ff14SB (Maier et al. 2015) and GAFF2 field were applied for describing protein and chemical ligand. The complex system was immersed into a rectangular periodic box of pre-equilibrated TIP3P water at least 10 Å distance around the complexes. Finally, an appropriate amount of sodium ions was added to maintain the electroneutrality of the simulation system.

For each simulation, a sophisticated protocol is followed, including minimisation, heating, equilibration, and production. Initially, the water molecules were minimised through 2500 steps of steepest descent followed by 2500 steps of conjugate gradient.

Figure 1. The flowchart of the technical strategy used in this study. Experimental methods include target prediction for YQCM’s compound and ARHL, construction and topological analysis on compound-target network and PPI network, enrichment analysis on GO and KEGG pathway, molecular docking, and in vitro study.
while proteins were kept at the position except for the hydrogens. The same minimisation protocol was applied to optimise the side chains. Then, the whole system was relaxed for 5000 steps without any restraints. After energy minimisation, each system was gradually heated at a constant volume from 0 K to 300 K over a coupling time of 100 ps with position restraints. After heating, the whole system was equilibrated over 100 ps at a constant pressure of 1 bar. Subsequently, another 100 ps pre-equilibration was performed for pressure relaxation with a weak restraint on the protein backbone. After that, a 100 ns MD simulation was conducted for each system to produce trajectories. During MD simulations, periodic boundary conditions were employed and the direct space interaction was calculated by using the Particle-Mesh Ewald (PME) method with long-range electrostatic interaction. The SHAKE algorithm was used to restrict the bond to the hydrogen atom (Kráutler et al. 2001). The time-step was set at 2 fs and the trajectory was saved every 10 ps for subsequent analysis. The MMPBSA.py module in AMBER 18 was used for Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations based on the MD trajectory (Miller et al. 2012).

**Preparation of YQCM decoction**

Astragali Radix, Ginseng Radix et Rhizoma, Glycyrrhizae Radix et Rhizoma, Cimicifugae Rhizoma, Puerariae Lobatae Radix, Astragali Radix, Ginseng Radix et Rhizoma, Glycyrrhizae radix et rhizome, and 187 in cimicifugae rhizome, 18 in vitisic fructus, 144 in phellodendri chinensis cortex, 140 in phellodendri chinensis cortex, 140 in Paeoniae Radix et Rhizoma, 140 in Paeoniae Radix et Rhizoma, 140 in Viticis Fructus, Phellodendri Chinensis Cortex, Paenoniae Radix Alba, purchased from Kanggiao Chinese Medicine Tablet Co., Ltd., were used to prepare YQCM decoction with the proportions as 10:10:10:6:6:3:2:2. All crude drugs were soaked in 60% ethanol for 0.5 h and then extracted with 60% ethanol 2 times for 1.5 h, respectively. Next, the ethanol extract was evaporated in vacuo until the relative density was 1.15. The YQCM powder was obtained by a freeze-dryer and stored at 4°C for later use.

**Liquid Chromatography-Mass Spectrometry**

Liquid chromatography-mass spectrometry was conducted on an LTQ Orbitrap XL™ hybrid FT mass spectrometer (ThermoFisher, Waltham, MA, USA). Liquid chromatographic separation was performed on an ACQUITY UPLC™ HSS T3 1.8 µm 2.1 × 100 mm column maintained at 35°C and eluted with gradient water. The mixture containing six reference components was used for the qualitative analysis: (1) puerarin, (2) ginsenoside-Rg1, (3) luteolin, (4) astragaloside IV, (5) kaempferol, and (6) formononetin.

**Western blot**

Proteins were extracted from treated cells and put through the 12% Protein Gel electrophoresis. After that, protein samples were transferred into the polyvinylidene fluoride membrane (Merck Millipore, Darmstadt, Germany) and blocked for 15 min with QuickBlock solution (Beyotime, Shanghai, China). Afterward, the blotted membrane was incubated with specific primary antibodies: anti-γH2AX (#9718, 1:1000, Cell Signalling Technology, USA), anti-cleaved caspase-3 (ASP175) (#9661, 1:1000, Cell Signalling Technology, Danvers, MA USA), anti-β-actin (#4970, 1:1000, Cell Signalling Technology, Danvers, MA) for overnight at 4°C. Then, each membrane was washed with TBS-T buffer and incubated with a secondary antibody for 1 h at room temperature. The blots were visualised by ECL Plus Western Blotting Substrate (Perkin Elmer, Waltham, MA, USA) and imaged by ChemiDOC™ Touch Imaging System (Bio-Rad, California, Hercules, USA) using standard chemiluminescence. Quantification of band intensity was analysed with Image Lab Software (Bio-Rad, California, Hercules, USA).

**Statistics analysis**

All statistical analyses were performed by GraphPad 7.0 (GraphPad Software, San Diego, USA). One-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test was applied for multiple group comparisons. P values < 0.05 were considered statistically significant. Data are expressed as the means ± standard deviation (SD).

**Results**

**Chemical compounds in YQCM decoction**

Using the TCMSP database, 87 compounds were found in Astragali radix, 190 in Ginseng radix et rhizoma, 280 in glycyrrhizae radix et rhizome, and 187 in cimicifugae rhizome, 18 in Puerariae lobatae radix, 144 in Viticis fructus, 140 in Phellodendri
chinensis cortex, 85 in Paeoniae radix alba. Among them, 206 compounds met the criteria of OB ≥ 30% and DL ≥ 0.18.

**Prediction of targets and construction of a visual network of YQCM ingredient-action target**

206 potential bioactive compounds were further searched on the Drugbank and TCMSP platform for target prediction and 233 corresponding potential targets were obtained. To illustrate the relationship between the compounds and their targets, a compound-target network was established via Cytoscape 3.6.0 (Figure 2). 395 nodes (162 nodes for candidate bioactive ingredients and 233 nodes for potential targets), as well as 2813 edges, were found in the network. According to topological analysis, the top 10 with the highest degree of nodes were quercetin, kaempferol, β-sitosterol, stigmasterol, formononetin, luteolin, isorhamnetin, fumarine, 7-O-methylisomucronulatol, 7-methoxy-2-methyl isoflavone (Table 1), which might be involved in the regulation of multiple ARHL targets.

![Figure 2. Network of the ingredient-action target. The blue oval cycle is on behalf of the active compound from YQCM. The yellow squares represent the compound’s target.](image)

**Table 1.** Characters of core compounds in YQCM decoction.

| Mol ID   | Mol name               | BC  | CC   | Degree |
|----------|------------------------|-----|------|--------|
| MOL000098| Quercetin              | 0.406 | 0.511 | 544     |
| MOL000422| Kaempferol             | 0.083 | 0.423 | 255     |
| MOL000358| beta-Sitosterol        | 0.027 | 0.398 | 104     |
| MOL000449| Stigmasterol           | 0.036 | 0.400 | 104     |
| MOL000392| Formononetin           | 0.026 | 0.388 | 84      |
| MOL000006| Luteolin               | 0.088 | 0.413 | 50      |
| MOL000354| Isorhamnetin           | 0.019 | 0.394 | 48      |
| MOL000707| Fumarine               | 0.008 | 0.378 | 38      |
| MOL000378| 7-O-Methylisomucronulat| 0.012 | 0.402 | 32      |
| MOL003896| 7-Methoxy-2-methyl isoflavone | 0.012 | 0.402 | 31      |

Betweenness Centrality: BC; Closeness Centrality: CC
ARHL-related gene

The keyword “Age-related hearing loss” and “Presbycusis” were used to search the reported ARHL-related genes in the two disease databases OMIM database and GeneCards database. A total of 1782 genes were obtained after removing duplicates. Common target genes between YQCM decoction and ARHL were acquired by overlapping the above targets via the Venn diagram. A total of 134 common targets were obtained as shown in Figure 3A.

Protein-Protein interaction network

Common target genes between YQCM decoction and ARHL were input into the STRING database. The protein-protein interaction of these common targets was constructed as a PPI network, in which the greater the degree of the node, the greater the role of the target in the network. According to the network topology properties, 52 targets with a degree greater than the median (Median of Betweenness = 0.0026; Median of Closeness = 0.5624; Median of Degree = 32) were predicted as the core targets of YQCM action on ARHL. In this network, AKT1, IL-6, MAPK3, VEGFA, CASP3, JUN, MAPK8, EGF, PTSG2, and MAPK1 were the top 10 nodes in terms of degree value (Table 2).

Enrichment analysis of gene ontology and KEGG pathway

To understand the function and the underlying significance of the YQCM’s therapeutic effect, the above 51 core targets were entered into the DAVID platform for GO term and KEGG pathways enrichment analysis. The results showed that the targets were mainly enriched in 45 molecular functions, 301 biological processes, and 28 cellular components. The top 10 enriched terms are shown in Figures 4A–C. We found that biological processes mainly concentrated on positive regulation of transcription from RNA polymerase II promoter, negative regulation of the apoptotic process, response to the drug, signal transduction, positive regulation of transcription, DNA-template, response to ethanol, ageing, response to hypoxia, angiogenesis.

The molecular functions were related to protein binding, enzyme binding, DNA binding, transcription factor binding, protein homodimerization activity, transcriptional activator activity, cytokine activity, etc. Finally, the cellular component was mainly composed of the nucleus, cytosol, nucleoplasm, extracellular space, cytoplasm, nuclear plasm, plasma membrane, extracellular region, mitochondrial, protein complex, and perinuclear region of cytoplasm, and so on. KEGG pathway analysis showed that the potential targets of YQCM action on ARHL were involved in 94 signalling pathways (p < 0.05). These pathways are predominantly involved in the HIF-1 pathway (consist of targets of CDKN1A, NOS3, EGF, STAT3, SERPINE1, HIF1A, EGFR, VEGFA, IL6, ERBB2, AKT1, MAPK1, HMOX1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3), FoxO (consist of targets of IL10, CDKN1A, EGF, STAT3, EGFR, IL6, MAPK8, CCND1, CAT, MDM2, AKT1, MAPK1, MAPK3). The top 10 KEGG enrichment pathway ranking p values according to the order from small to large are displayed in Figure 4D.

Molecular docking of main chemical compounds binding to hub genes

The ten candidate therapeutic targets with high degree value, AKT1, IL6, MAPK3, VEGFA, CASP3, JUN, MAPK8, PTSG2,
EGF, and MAPK1, were docked with the ten core active compounds of YQCM. The lowest binding energy of the molecular docking of the core targets and compounds was presented in the heatmap as shown in Figure 5. We found all docking values were lower than $-5$ kcal/mol, indicating a stable combination between core targets and core compounds (Yang et al. 2021; Figure 4. Enrichment analysis of Gene ontology and KEGG pathway. 52 targets with a degree greater than the median were applied for enrichment analysis. Gene Ontology including biological processes (A), cellular components (B), molecular functions (C), and KEGG pathway (D) was analysed by DAVID. The statistical significance threshold of enrichment analysis was established at $p < 0.05$.

Figure 5. Heatmap of molecular docking results. The x-axis represents ten core active bioactive compounds; the y-axis represents the hub targets. The docking score represents the lowest binding energy of compounds-target molecular docking (kJ/mol).
Zhang et al. 2021). In particular, AKT, PTSG2, and CASP3 were found to have a strong binding affinity with all ten key compounds, values ranging from -7.6 to -11.2 kcal/mol.

Molecular dynamics simulation

Molecular dynamics simulation was used for studying the binding stability of the top ten protein-compound with the best molecular docking scores. The MM/GBSA method was further used to calculate the binding energies. The specific binding free energy of AKT1_7-Metho-2-met_isoflavone, AKT1_β-sitosterol, AKT1_fumarine, AKT1_luteolin, AKT1_quercetin, AKT1_stigmasterol, CASP3_stigmasterol, MAPK8_fumarine, PTGS2_β-sitosterol, PTGS2_fumarine was shown in Table 3. The highest binding free energy combinations were CASP3_Stigmasterol (-42.509 kcal/mol) and AKT1_β-sitosterol (-39.354 kcal/mol), followed by AKT1_Stigmasterol (-39.024 kcal/mol). And the MD simulation indicated that the combination of AKT and the main chemical compounds was relatively stable. Our analysis showed that these high binding free energy combinations were mainly contributed by van der Waals energy, electrostatic energy, and non-polar energy. The root-mean-square deviation (RMSD) curve represents the stability of the protein conformation. The RMSD pattern of protein and molecule during the 100 ns simulations was shown in Figure 6. As can be seen, the RMSD values of the black curve (protein) were maintained below 3.0 Å and the RMSD values of the red curve (molecule) were less than 2.0 Å, indicating the stability of the docked complex (Ramirez and Caballero 2018). It is worthy to note that the complexes of AKT1_luteolin (Figure 6D), AKT1_quercetin (Figure 6E), CASP3_stigmasterol (Figure 6F), and MAPK8_fumarin (Figure 6H) possessed a non-fluctuating RMSD curve during MD, which indicates that the binding between the protein and the molecule is extremely stable.

Experimental validation

To evaluate YQCM’s cytotoxicity on the HEI-OC1 cells, cells were treated with 0, 50, 75, 100, 125, 250, and 500 μg/mL of YQCM for 24h. As displayed in Figure 7A, YQCM did not show cytotoxicity up to 125 μg/mL. Next, we investigated the cell viability with and without YQCM pre-treatment under oxidative conditions. The results revealed that compared with the control group, the viability of cells exposed to H2O2 (100 μM) was significantly reduced by 68% (Figure 7B). However, YQCM (10, 30, and 90 μg/mL) showed a concentration-dependent recovery of cell viability, which were 88.07, 91.73, and 97.45%, respectively.

Phase II

Phase II study was conducted to determine the bioavailability of AKT, PTSG2, and CASP3 in vivo. The results showed that AKT, PTSG2, and CASP3 were significantly reduced by 68% (Figure 7B). However, YQCM (10, 30, and 90 μg/mL) showed a concentration-dependent recovery of cell viability, which were 88.07, 91.73, and 97.45%, respectively.

Discussion

Age-related hearing loss always exhibits a mixture of pathological changes within the sensory hair cells, auditory neurons, SGNs and stria vascularis (Keithley 2020). With the characteristics of multiple targets, Chinese herbal medicines may be beneficial to the treatment of ARHL. Preliminary clinical observations have shown that YQCM and its herbs may restore hearing loss in the elderly (Li 2013; Wei et al. 2017). These data raised the question of what underlying molecular mechanisms could explain YQCM’s protective effect on hearing function? To elucidate it, we attempted to use network pharmacology to show the interaction of the bioactive compounds, target molecules, and biological functions.

In our network pharmacology study, 206 potential compounds retrieved from YQCM were considered pharmacokinetically active and probably absorbed and distributed in the human body. The top 10 compounds with high degrees were quercetin, kaempferol, β-sitosterol, stigmasterol, luteolin, isorhamnetin, fumarine, 7-O-methylisomucronulatol, 7-methoxy-2-methyl isoflavone. Quercetin and kaempferol, the dominant flavonoid found generally in plants, have been reported to exhibit antioxidant and anti-inflammatory effects (Di Petrillo et al. 2022). Quercetin-mediated oxidative stress clearance and anti-apoptosis have been proven to attenuate noise-induced hearing loss and protect against hair cell loss induced by neomycin (Hirose et al. 2016). Many research groups have reported flavonoid luteolin’s protective effect on heart function via blocking oxidative stress, decreasing inflammation, ameliorating apoptosis, and up-regulating autophagy (Luo et al. 2017). Similar protective effects on auditory function were observed recently. Choi et al. (2008) firstly tested the luteolin for its antioxidant activity using the auditory hair cell HEI-OC1 in vitro. This study indicated that luteolin markedly enhances HO-1 expression via activation of the ERK, thereby blocking cisplatin-induced oxidative damage and apoptosis. Another study showed luteolin effectively protects against oxidative stress-induced cellular senescence through p53 and SIRT1 in HEI-OC1 (Zhu et al. 2021). These results further support that luteolin’s protective effect on HEI-OC1 cells may help improve hearing function. β-Sitosterol and stigmasterol are two compounds that have received attention in recent years in aging and neurodegenerative diseases for their ability to cross the blood-brain barrier and exhibit important activities related to
removing Aβ plaque and reducing neuroinflammation (Sharma et al. 2021). The diverse and promising effects from these compounds might contribute to YQCM decoction as a potential therapeutic agent for age-related hearing loss.

In this study, AKT1, IL6, VEGFA, Caspase-3, JUN, MAPK8, PTGS2, EGF, and MAPK1 are the top 10 nodes with the highest degree value. It was speculated that they might be the key targets involved in YQCM against ARHL. We conduct molecular
docking for main chemical compounds binding to these hub targets. The results showed that most of the core chemical compounds have good docking affinities with hub targets, especially AKT1, PTGS2, and Caspase-3. Notably, the RMSD curves of the complexes of AKT1_luteolin, AKT1_quercetin, and CASP3_stigmasterol did not fluctuate in MD simulation, indicating that the binding between the protein and the molecule is very stable. Akt has been considered a pivotal anti-apoptotic factor in many different cell death paradigms (Zheng et al. 2020). Many studies have reported that compounds from herbal medicine could interact with Akt resulting in beneficial neuroprotective effects. For instance, flavanones could activate Akt/PKB signalling pathway and show prosurvival characteristics in the cortical neurons (Vauzour et al. 2007). Akt also plays a critical role in the cochlea for its phosphorylation of numerous downstream proteins, including caspase-3, and contributes to hair cell death (Haake et al. 2009; Sha et al. 2010). Besides hair cell death, recent data suggest inflammation is also the cause of age-related hearing loss (Verschuur et al. 2012). The hub gene, PTGS2, encoding the enzyme of cyclooxygenase-2 (COX-2),
which is an important immune mediator, plays an imperative role in the ageing process. A recent study by Uraguchi et al. (2021) analysed 84 immune-related genes expression in the cochlea of 12-month-old mice with ARHL as compared to the young control mice. They found around 40% of immune-related genes were upregulated in the aged cochlea, including PTGS2. And PTGS2 were immunolocalized ubiquitously in aged cochlear structures, including the lateral wall (the stria vascularis and spiral ligament).

Notably, in this study, KEGG enrichment results showed that HIF-1, FoxO, and PI3K/AKT pathways were significantly associated with YQCM’s action on ARHL. It has been reported that HIF-1 pathways are closely related to the occurrence and development of age-related hearing loss. Cochlear hypoxia-inducible factor-1alpha (HIF-1α) levels were dramatically increased in the age-related hearing loss mice model (Riva et al. 2007; Hwang et al. 2013; Lin et al. 2017), especially in the spiral ganglion and the stria vascularis. Activation of HIF-1 might be related to cochlear injury induced by free radicals and appeared to be responsive to regulating target genes, involved in pathways of apoptosis with the caspase-3 protein (Hwang et al. 2013; Deal et al. 2017). In contrast, a recent study by Pak et al. (2019) revealed that CoCl2 pre-treatment protected auditory hair cells from H2O2-mediated cell death via the activation of the HIF-1α. This study proved that HIF-1 could ameliorate oxidative stress via redox-sensitive transcription factors nuclear factor erythroid 2-related factor 2 (Nrf-2), and improve an antioxidant enzyme peroxiredoxin 6 (Prdx6) in preventing auditory cell damage during ARHL. FoxO is a well-studied pathway affected by ototoxic drugs, which is one of the factors in increasing ROS production in ARHL. For example, the FoxO signalling pathway was activated following amikacin-induced ototoxicity which is consistent with increased apoptosis (Liu et al. 2017), or neomycin-induced ototoxicity which is related to decreased expression of antioxidant enzymes (Liu et al. 2016). Although the direct evidence that FoxO responds to age-related hearing loss is sparse, accumulating evidence indicates that misregulation of the FoxO signalling pathway may underlie both age-associated functional decline involving oxidative stress resistance, DNA damage repair, and apoptosis. Our KEGG analysis also predicted another pathway, PI3K/AKT, as the main pathway underlying the mechanism of YQCM’s protection effect on ARHL. During the past decade, emerging evidence has indicated that PI3K/AKT is the main upstream pathway for preventing and rescuing cochlea injury in maintaining cellular oxidative homeostasis via enhancing the downstream antioxidant factors (Tomobe et al. 2012; Zhu et al. 2018; Liu et al. 2021), downregulating the expression of proteins responsible for apoptosis (Kucharava et al. 2019; Zhang et al. 2021), etc.

Through enrichment analysis on the GO terms, we found that the therapeutic targets showed a strong correlation with the biological processes of negative regulation of the apoptotic process. 35% of core therapeutic targets (18/51) of YQCM were enriched in this process, including AKT1, GSK3B, CDKN1A, CASP3, MYC, CAT, BCL2L1, etc. Increaseasment of ROS production in ARHL, in addition to reduced antioxidant activity with age, will exacerbate the ROS-antioxidant imbalance (Tavanai and Mohammadkhani 2017). Furthermore, excessive ROS production adversely affects mitochondrial DNA (mtDNA), leading to extreme dysregulation in oxidative phosphorylation, further increasing ROS production (Chen and Tang 2014). Ultimately, the higher production of ROS may change DNA structure, resulting in cell death, including apoptosis, necrosis, and necroptosis (Tawfik et al. 2020) or cellular senescence (Menardo et al. 2012; Benkafadar et al. 2019), resulting in degenerative changes in the cochlear. To verify the results from GO function analysis, we set up a condition of oxidative stress in auditory hair cell culture with 100 μM H2O2. Pre-treatment of YQCM increased cell viability in HEI-OC1 cells exposed for 3 h to H2O2. Phosphorylation of the Ser-139 residue of the histone variant H2AX, forming γH2AX, is a sensitive marker for the appearance of DNA double-strand breaks (Mah et al. 2010). In our study, the level of γH2AX was markedly raised in HEI-OC1 cells treated with 100 μM H2O2 for 3 h, while pre-treatment of YQCM can significantly reduce the γH2AX level (Figure 7E), indicating that the presence of YQCM could inhibit oxidative stress-induced DNA damage. YQCM also reduced HEI-OC1 cell’s apoptosis under oxidative stress by improving mitochondrial membrane potential, decreasing the level of cleaved caspase-3, suggesting that the negative regulation of apoptosis might be involved in YQCM protecting cell death from oxidative stress. Although the detailed molecular pathways involved in modulating auditory hair cell death remain to be identified, our network pharmacology and experiment data suggest that YQCM decocion may be against DNA damage and apoptosis induced by oxidative stress.

Conclusions

For the first time, network pharmacology and molecular docking strategy were utilised to explore the underlying mechanism of YQCM in treating ARHL. Our network pharmacology data suggest that modulations of DNA damage and apoptosis might be the key protective role for YQCM decoction. Potential hub targets for YQCM such as AKT1, CASP3, and PTGS2 may be exploited as potential strategies. We used molecular docking analysis and MD simulation to validate the interaction between core targets and compounds. Additionally, the protective effect of YQCM on ARHL and its mechanism were supported by the evidence that YQCM could alleviate oxidative stress-induced auditory hair cell death via modulating DNA damage/apoptosis. Future experiments using molecular methods and animal models as well are needed to support the current findings. Nevertheless, the results of this study provide an important basis for further research on the mechanism of YQCM in ARHL. This study proved that bioinformatics analysis combined with molecular docking and cell model is a promising method to explore other possible pharmacological interventions of ARHL.

Authors contributions

YFY and RXW performed the network pharmacology-based analysis and molecular docking. YFY, XRY and NL conducted the in vitro experiments. XRY and MC carried out the preparation of YQCM. Quality control analysis of YQCM was completed by SPF. QL and YFY searched the database and performed data analysis. YFY prepared the manuscript. QL, YD, and JRS reviewed the manuscript. QL designed the experiment and supervised the project. All authors approved the final submitted version of the manuscript.

Disclosure statement

The author declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Funding

This work was supported by the National Natural Science Foundation of China (82074141 and No.81774020).

References

Armstrong AG, Lam CC, Sabesan S, Lesica NA. 2022. Compression and amplification algorithms in hearing aids impair the selectivity of neural responses to speech. Nat Biomed Eng. 6(6):717–730.

Benkafadar N, Francois F, Affortit C, Casas F, Ceccato JC, Menardo J, Venail F, Maltry-Camime B, Puel JL, Wang J. 2019. ROS-induced activation of DNA-PK-C. B responses increases senscence-like state in postmitotic cochlear cells: implication for hearing preservation. Mol Neurobiol. 56(8):5950–5969.

Chen H, Tang J. 2014. The role of mitochondria in age-related hearing loss. Biogerontology. 15(1):13–19.

Choi BM, Lim DW, Lee JA, Gao SS, Kwon DY, Kim BR. 2008. Luteolin suppresses cisplatin-induced apoptosis in auditory cells: possible mediation through induction of heme oxygenase-1 expression. J Med Food. 11(2):230–236.

Choung YH, Kim SW, Tian C, Min JY, Lee HK, Park SN, Lee JB, Park K. 2011. Korean red ginseng prevents gentamicin-induced hearing loss in rats. Laryngoscope. 121(6):1294–1302.

Dea JA, Betz J, Yaffe K, Harris T, Purchase-Helzner E, Satterfield S, Pratt S, Govil N, Simonsick EM, Lin FR. 2017. Hearing impairment and incident dementia and cognitive decline in older adults: the health ABC Study. J Gerontol A Biol Sci Med Sci. 72(5):703–709.

Di Petrollo A, Orru G, Fais A, Fantini MC. 2012. Quercetin and its derivatives as antioxidant potentials: a comprehensive review. Phytother Res. 36(1):266–278.

Doosti A, Lotfi Y, Moossavi A, Bakhshi E, Talasaz AH, Hoorzad A. 2014. Comparison of the effects of N-acetyl-cysteine and ginseng in prevention of cisplatin-induced hearing loss in male workers. Noise Health. 16(71):223–227.

Haake SM, Dinh CT, Chen Y, Zhang M. 2021. Clinical efficiency of Yi-qi Cong-Ming decoction combined with donepezil in the treatment of Alzheimer’s disease in Chinese patients. Med J Chinese People Health. 33(5):92–94. Chinese.

Keithley EM. 2020. Pathology and mechanisms of cochlear aging. J Neurosci Res. 98(9):1674–1684.

Krautler V, van Gunsteren WF, Hünenberger PH. 2001. A fast SHAKE algorithm to solve distance constraints: applications for small molecules in molecular dynamics simulations. J Comput Chem. 22(5):501–508.

Kucharova K, Sekulic-Jalabovic M, Horvath L, Bodmer D, Petekovic V. 2019. Passiteodrol protects mammalian cochlear hair cells from gentamicin ototoxicity by activating the PI3K/Akt and NFkappaB signaling. Hear Res. 255(1-2):22–32.

Kang W, Chen Y, Zhang M. 2021. Clinical efficacy of Yi-qi Cong-Ming decoction combined with donepezil in the treatment of Alzheimer’s disease in Chinese patients. Med J Chinese People Health. 33(5):92–94. Chinese.

Lin FR, Albert M. 2014. Hearing loss and dementia – who is listening? Aging Ment Health. 18(10):671–677.

Lin Y, Shen J, Li D, Ming J, Liu X, Zhang N, Lai J, Shi M, Ji Q, Xing Y. 2017. MiR-34a contributes to diabetes-related cochlear hair cell apoptosis via SIRT1/HIF-1alpha signaling. Gen Comp Endocrinol. 246:63–70.

Liu J, Chen Y, Qi J, Zhang Y, He Y, Ni W, Li W, Zhang S, Sun S, Taketo MM, et al. 2016. WNT activation protects against neomycin-induced hair cell damage in the mouse cochlea. Cell Death Dis. 7:e2135.

Liu S, Xu T, Wang X. Sun M, Xu T, Wang A. 2017. FoxO3a plays a key role in the protective effects of pomegranate peel extract against amikacin-induced ototoxicity. Int J Mol Med. 40(1):175–181.

Liu W, Xu L, Wang X, Zhang D, Sun G, Wang M, Wang M, Han Y, Chai R, Wang H. 2021. PROX1 activates autophagy via the PTEN-AKT signaling pathway to protect against cisplatin-induced spiral ganglion neuron damage. Autophagy. 17(12):4159–4181.

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Braye C, Burns A, Cohen-Mansfield J, Cooper C, et al. 2020. Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet. 396(10248):413–446.

Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, et al. 2017. Dementia prevention, intervention, and care. Lancet. 390(10113):2673–2734.

Loughrey DG, Kelly ME, Kelley GA, Brennan S, Lawlor BA. 2018. Association of age-related hearing loss with cognitive function, cognitive impairment, and dementia: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 144(2):115–126.

Luo Y, Shang P, Chen H, Tang J. 2014. The role of mitochondria in age-related hearing loss. Biogerontology. 15(1):13–19.

Maharani A, Pendleton N, Leroi I. 2019. Hearing impairment, loneliness, social isolation, and cognitive function: longitudinal analysis using English longitudinal study on ageing. Am J Geriatr Psychiatry. 27(12):1348–1356.

Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. 2015. f145B: Improving the accuracy of protein side chain and backbone parameters from ff09SB. J Chem Theory Comput. 11(8):3696–3713.

McCormack A, Fortnum H. 2013. Why do people fitted with hearing aids not wear them? Int J Audiol. 52(3):360–368.

Menardo J, Tang Y, Ladrech S, Lenoir M, Casas F, Michel C, Bourien J, Ruel J, Rebillard G, Maurice T, et al. 2012. Oxidative stress, inflammation, and autophagic stress as the key mechanisms of premature age-related hearing loss in SAMP8 mouse Cochlea. Antioxid Redox Signal. 16(3):263–274.

Miller BE, McGrane RD, Smith HM, Homey Z, Goh F, Hoebig AE. 2012. MMPBPSA:py: an efficient program for end-state free energy calculations. J Chem Theory Comput. 8(9):3314–3321.

Pak JH, Kim Y, Yi J, Chung JW. 2020. Antioxidant therapy against oxidative damage of the inner ear: protection and preconditioning. Antioxidants. 9(1):1076.

Pak JH, Yi J, Ryu S, Kim IK, Kim JW, Bak H, Chung JW. 2019. Induction of Redox-active gene expression by CoCl2 ameliorates oxidative stress-mediated injury of murine auditory cells. Antioxidants. 8(9):399.

Park J, McDonald JJ, Petter RC, Houk KN. 2016. Molecular dynamics analysis of binding of kinase inhibitors to WT EGFR and the T790M mutant. J Chem Theory Comput. 12(4):2066–2078.

Pawlak R, McKinnon BJ. 2018. Hearing loss in the elderly. Clin Geriatr Med. 34(2):163–174.

Qu H, Li N, Li J, Wang H. 2019. Meta-analysis of Yaqi Congming decoction in treating senile dementia. Clin J Trad Chin Med. 31:1857–1862. Chinese.

Ramirez D, Caballero J. 2018. Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? Molecules. 23(5):1038.

Riva C, Donadiu E, Magnan J, Lavielle JP. 2007. Age-related hearing loss in CD1 mice is associated to ROS formation and HIF target proteins up-regulation in the cochlea. Exp Gerontol. 42(4):327–336.

Sha SH, Chen FQ, Schacht J. 2010. PTEN attenuates PIP3/Akt signaling in the cochlea of the aging CBA/J mouse. Hear Res. 264(1-2):86–92.

Shibata SB, Budenz CL, Bowling SA, Pfingst BE, Raphael Y. 2011. Nerve terminal degeneration in aging Chinese. Biogerontology. 12(12):1021–1031.

Tomobe K, Shinozuka T, Kuroiwa M, Nomura Y. 2012. Age-related changes in DNA damage responses drives senescence-like state in postmitotic cochlear cells: implication for hearing preservation. Mol Neurobiol. 56(8):5950–5969.

Wang H. 2021. PRDX1 activates autophagy via the PTEN-AKT signaling pathway to protect against cisplatin-induced spiral ganglion neuron damage. Autophagy. 17(12):4159–4181.
Vauzour D, Vafeiadou K, Rice-Evans C, Williams RJ, Spencer JP. 2007. 
Activation of pro-survival Akt and ERK1/2 signalling pathways underlie 
the anti-apoptotic effects of flavanones in cortical neurons. J Neurochem. 
103(4):1355–1367.

Verschuur CA, Dowell A, Syddall HE, Ntani G, Simmonds SJ, Baylis D, Gale 
CR, Walsh B, Cooper C, Lord JM, et al. 2012. Markers of inflammatory 
status are associated with hearing threshold in older people: findings from 
the Hertfordshire ageing study. Age Ageing. 41(1):92–97.

Wang J, Cieplak P, Kollman PA. 2000. How well does a restrained electrostatic 
potential (RESP) model perform in calculating conformational energies of 
organic and biological molecules? J Comput Chem. 21(12):1049–1074.

Wei G, Chen J, Qiao F. 2017. Clinical observation on the therapeutic effect 
of Yiqi Congming decoction in treating hear loss. Chin Med Biochem 
Pharmacol. 8(37):58–61. Chinese.

Xiong M, He Q, Lai H, Huang W, Wang L, Yang C. 2012. Radix astragali 
injection enhances recovery from sudden deafness. Am J Otolaryngol. 
33(5):523–527.

Xiong M, He Q, Wang J, Lai H. 2011. Astragalosides reduce cisplatin ototox-
icty in guinea pigs. ORL J Otorhinolaryngol Relat Spec. 73(3):131–136.

Yamasoba T, Lin FR, Someya S, Kashio A, Sakamoto T, Kondo K. 2013. 
Current concepts in age-related hearing loss: epidemiology and mechanis-
tic pathways. Hear Res. 303:30–38.

Yang Y, He Y, Wei X, Wan H, Ding Z, Yang J, Zhou H. 2021. Network 
pharmacology and molecular docking-based mechanism study to reveal 
the protective effect of salvianolic acid C in a rat model of ischemic 
stroke. Front Pharmacol. 12:799448.

Zhang X, Gao R, Zhou Z, Tang X, Lin J, Wang L, Zhou X, Shen T. 2021. A 
network pharmacology based approach for predicting active ingredients 
and potential mechanism of Lianhuaqingwen capsule in treating COVID-
19. Int J Med Sci. 18(8):1866–1876.

Zhang Y, Lv Z, Liu Y, Cao H, Yang J, Wang B. 2021. PIN1 protects hair cells 
and auditory HEI-OC1 cells against senescence by inhibiting the PI3K/ 
Akt/mTOR pathway. Oxid Med Cell Longev. 2021:9980444.

Zheng Z, Wang Y, Yu H, Li W, Wu J, Cai C, He Y. 2020. Salvianolic acid B 
inhibits ototoxic drug-induced ototoxicity by suppression of the mito-
chondrial apoptosis pathway. J Cell Mol Med. 24(12):6883–6897.

Zhu RZ, Li BS, Gao SS, Seo JH, Choi BM. 2021. Luteolin inhibits H2O2-
duced cellular senescence via modulation of SIRT1 and p53. Korean J 
Physiol Pharmacol. 25(4):297–305.

Zhu WY, Jin X, Ma YC, Liu ZB. 2018. MIF protects against oxygen-glucose 
deprivation-induced ototoxicity in HEI-OC1 cochlear cells by enhance-
ment of Akt-Nrf2-HO-1 pathway. Biochem Biophys Res Commun. 503(2): 
665–670.